Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids
about
Postprandial Metabolism of Macronutrients and Cardiometabolic Risk: Recent Developments, Emerging Concepts, and Future Directions.Pediatric Metabolic Syndrome: Pathophysiology and Laboratory AssessmentRole of the Enterocyte in Fructose-Induced HypertriglyceridaemiaSitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans.Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humansGlucagon-like peptide-2 regulates release of chylomicrons from the intestine.Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.The Regulation of Lipid Deposition by Insulin in Goose Liver Cells Is Mediated by the PI3K-AKT-mTOR Signaling Pathway.Deregulated Lipid Sensing by Intestinal CD36 in Diet-Induced Hyperinsulinemic Obese Mouse Model.Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol.Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance.Gut-liver interaction in triglyceride-rich lipoprotein metabolism.Short Term Palmitate Supply Impairs Intestinal Insulin Signaling via Ceramide Production.Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment.A novel method for measuring intestinal and hepatic triacylglycerol kinetics.Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2.Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.Risk prediction with triglycerides in patients with stable coronary disease on statin treatment.Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.
P2860
Q30362026-ABAC69CF-CD91-4AC9-9E4E-2F376722BD54Q33551642-253E20D9-FCBA-466A-9F03-E3588199A6D3Q33616687-AC682B97-4A61-4722-A076-6A5219E3BAB1Q33789371-B8A40F58-93D8-4E0E-BC13-F2B22C4C30AEQ34526962-E47EB966-3148-4456-91D9-77F31570C9EBQ35046115-750E68BC-9ED4-4D1C-AD8C-82B72625AD56Q35186665-7AD9D6BD-0C05-458D-865F-8323EFFF3242Q35623077-5453E9FA-8A9A-4445-8E0D-23F35642062DQ35883898-23B7B68C-B129-409A-9D92-CA9EEF0854F9Q37333546-0C9624D8-E0B7-4CBF-98D4-B6E4AF55B360Q37590276-5043DB10-95F5-4D2D-81A4-510DED26B454Q37892758-0EE6F1B9-A2FC-4670-ACDE-1A20E44ECAACQ42395469-A0965710-A504-4E55-8A2A-C6872EC30015Q42635500-45ED7149-8DE6-42B6-ACE4-01AEF44DA02FQ44426071-B6128F16-8A97-47CD-A4AE-3CCC43178EDCQ49926115-D7704375-E124-4464-AD2A-6623EA627B37Q50976554-0B30F949-AC4D-45AB-A6DE-6C80B761F1E3Q51319217-ADC701D4-A9EF-4F18-B8E6-B1548A06FA29Q51381989-106504D8-9544-407E-BAA5-0D82EC20D81CQ55001495-4AAD4ECD-3854-47C7-A401-26389F35F52E
P2860
Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Insulin acutely inhibits intes ...... essing plasma free fatty acids
@ast
Insulin acutely inhibits intes ...... essing plasma free fatty acids
@en
type
label
Insulin acutely inhibits intes ...... essing plasma free fatty acids
@ast
Insulin acutely inhibits intes ...... essing plasma free fatty acids
@en
prefLabel
Insulin acutely inhibits intes ...... essing plasma free fatty acids
@ast
Insulin acutely inhibits intes ...... essing plasma free fatty acids
@en
P2093
P2860
P921
P356
P1433
P1476
Insulin acutely inhibits intes ...... essing plasma free fatty acids
@en
P2093
Gary F Lewis
Linda Szeto
Mirjana Pavlic
P2860
P304
P356
10.2337/DB09-1297
P407
P577
2009-12-22T00:00:00Z